Improving biopharma BD with AI-powered due diligence
In biopharma business development, companies face increasing pressure to identify the next blockbuster drug with limited resources and time constraints.
In-licensing
Chinese biotechs & assets, a Q&A with Kanya Rajangam, MD, PhD
Recently, I had a conversation with Dr. Kanya Rajangam, to discuss current perceptions about Chinese biotech, opportunities, language challenges, and risks.
The Great Disruption: how Chinese assets will reshape drug development
Chinese biopharma companies are at an inflection point, with rapid advances in science, know-how, and talent; these assets will reshape drug development.
AI for biopharma business development: finding the right assets faster
By combining human expertise with AI-powered analysis, we’re helping biopharma companies make faster, more informed business development decisions.